Literature DB >> 15857845

Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome?

U Jacobi, E Waibler, P Schulze, J Sehouli, G Oskay-Ozcelik, T Schmook, W Sterry, J Lademann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15857845     DOI： 10.1093/annonc/mdi204

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  26 in total

1.  The effect of seasonal variation and secretion of sunitinib in sweat on the development of hand-foot syndrome.

Authors:  Nienke A G Lankheet; Alwin D R Huitema; Henk Mallo; Sandra Adriaansz; John B A G Haanen; Jan H M Schellens; Jos H Beijnen; Christian U Blank
Journal:  Eur J Clin Pharmacol       Date:  2013-08-31       Impact factor: 2.953

Review 2.  Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities.

Authors:  Christian Kollmannsberger; Georg Bjarnason; Patrick Burnett; Patricia Creel; Mellar Davis; Nancy Dawson; Darren Feldman; Suzanne George; Jerome Hershman; Thomas Lechner; Amy Potter; Eric Raymond; Nathaniel Treister; Laura Wood; Shenhong Wu; Ronald Bukowski
Journal:  Oncologist       Date:  2011-04-13

3.  Squamous cell carcinoma of the oral cavity in nonsmoking women: a new and unusual complication of chemotherapy for recurrent ovarian cancer?

Authors:  Timothy L Cannon; Dominic W Lai; David Hirsch; Mark Delacure; Andrea Downey; Alexander R Kerr; Michael Bannan; Eleni Andreopoulou; Tamar Safra; Franco Muggia
Journal:  Oncologist       Date:  2012-05-23

4.  Localized palmar-plantar epidermal hyperplasia associated with use of sorafenib.

Authors:  Demet Cicek; Basak Kandi; Ferda A Dagli; Aziz Karaoglu; Beyzan D Haligur
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

5.  Fas/Fas ligand mediates keratinocyte death in sunitinib-induced hand-foot skin reaction.

Authors:  Chun-Nan Yeh; Wen-Hung Chung; Shih-Chi Su; Yen-Yang Chen; Chi-Tung Cheng; Yen-Ling Lin; Wan-Chun Chang; Rosaline Chung-Yee Hui; Kun-Chun Chiang; Tsung-Wen Chen; Yi-Yin Jan; Chien-Wei Chen; Ting-Jui Chen; Chih-Hsun Yang; Shuen-Iu Hung
Journal:  J Invest Dermatol       Date:  2014-05-06       Impact factor: 8.551

Review 6.  Prevention strategies for chemotherapy-induced hand-foot syndrome: a systematic review and meta-analysis of prospective randomised trials.

Authors:  Lígia Traldi Macedo; Joao Paulo Nogueira Lima; Lucas Vieira dos Santos; Andre Deeke Sasse
Journal:  Support Care Cancer       Date:  2014-01-26       Impact factor: 3.603

7.  Candidate mechanisms for capecitabine-related hand-foot syndrome.

Authors:  Gérard Milano; Marie-Christine Etienne-Grimaldi; Mireille Mari; Sandra Lassalle; Jean-Louis Formento; Mireille Francoual; Jean-Philippe Lacour; Paul Hofman
Journal:  Br J Clin Pharmacol       Date:  2008-03-13       Impact factor: 4.335

8.  Pegylated liposomal doxorubicin in the management of ovarian cancer.

Authors:  Gabriella Ferrandina; Giacomo Corrado; Angelo Licameli; Domenica Lorusso; Gilda Fuoco; Salvatore Pisconti; Giovanni Scambia
Journal:  Ther Clin Risk Manag       Date:  2010-10-05       Impact factor: 2.423

Review 9.  The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis.

Authors:  Alyssa Fischer; Shenhong Wu; Alan L Ho; Mario E Lacouture
Journal:  Invest New Drugs       Date:  2013-01-24       Impact factor: 3.850

10.  Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review.

Authors:  Ming J Poi; Michael Berger; Maryam Lustberg; Rachel Layman; Charles L Shapiro; Bhuvaneswari Ramaswamy; Ewa Mrozek; Erin Olson; Robert Wesolowski
Journal:  Support Care Cancer       Date:  2013-05-19       Impact factor: 3.603
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.